Bausch Health (TSX:BHC) FFO


TSX:BHC Bausch Health Companies Inc TSX:BHC
64 GF Score
Price C$7.49
GF Value C$11.06
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Bausch Health FFO?

FFO (Funds from operations) only applies to REITs.

TSX:BHC
64GF Score
Bausch Health Companies Inc TSX:BHC
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bausch Health (TSX:BHC) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued. The current stock price of C$7.49 is trading 32.3% below its estimated GF Value™ of C$11.06. GuruFocus considers Bausch Health to be Possible Value Trap.

Key valuation signals for TSX:BHC:

  • FFO:
  • GF Value™: C$11.06 vs. price of C$7.49 (32.3% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the TSX:BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch Health Business Description

Address 2150 St Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
64GF Score

Get the complete analysis for TSX:BHC

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$7.49
Price
C$11.06
GF Value